Effect of SBRT With Sequential Tislelizumab and Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
Lancet Respir Med 2024 Sep 18;[EPub Ahead of Print], ZR Zhao, SL Liu, T Zhou, G Chen, H Long, XD Su, X Zhang, JH Fu, P Lin, LJ Zhang, TH Rong, JD Wu, ZC Li, HL Su, JY Chen, YP Yang, YB Lin, M Xi, H YangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.